Skip Navigation

  1. About Us
    1. Overview
    2. History
    3. Recognition
    4. Offices
  2. Our Practice
    1. Practice Areas
      1. Patents, Utility Models, and Industrial Designs
      2. Trademarks
      3. Copyrights
      4. Corporate, Commercial and Business Law
      5. IP Litigation, Alternative Dispute Resolution
      6. Regulatory Law
      7. Licensing, Tech Transfer & Franchising
      8. Anti-Piracy, Anti-Counterfeiting & Enforcement
    2. Industry Groups
      1. Media, Sports & Entertainment Law Group
      2. Life Science & Pharmaceutical Law Group
  3. Our People
    1. Partners
      1. Sergio L. Olivares, Sr. † (1931-2010)
      2. Sergio L. Olivares, Jr.
      3. Luis C. Schmidt
      4. Cesar Ramos, Jr.
      5. Antonio Belaunzaran
      6. Gustavo A. Alcocer
      7. Jose Ignacio De Santiago
      8. Alejandro Luna
      9. Alonso Camargo
      10. Daniel Sanchez
    2. Associates (A - M)
      1. Osvaldo Amaral
      2. Armando Arenas
      3. Sofía Arroyo
      4. Guillermo Ballesteros
      5. Varinia Calleros
      6. Abraham Diaz
      7. Georgina Flores
      8. Pedro Herrera
      9. Carlos Maya
    3. Associates (N - Z)
      1. Mauricio Narváez
      2. Víctor Ramírez
      3. Sergio Rangel
      4. Maria del Carmen Sada
      5. Juan Luis Serrano
      6. Guillermo Treviño
      7. Carlos Woodworth
    4. All Attorneys / Engineers
    5. Firm Administration
  4. Knowledge & Resources
    1. Articles
      1. Trademark Law Articles
        1. Use requirements
        2. Approach to composite marks changed, again
        3. Life Sciences Handbook 2011 - Country Q&A
        4. Mexico should accept secondary meaning
        5. Getting the Deal Through - Trademarks 2011
        6. Pharmaceutical Trademarks 2010/2011 - A Global Guide
        7. No legal basis for banning names derived from INNs
        8. How Latin America tackles cutting-edge IP issues
        9. Specialised IP court corrects IMPI
        10. Protecting trade dress
        11. 43 more items...
      2. Patent Law Articles
        1. Getting the Deal Through - Patents 2012
        2. Surge of Patent Application Final Rejections Provides Unique Opportunity for Patent Precent Making
        3. Mexico issues regulations to approve biologic drugs
        4. Latin America Roundtable
        5. New regulations pending
        6. The International Comparative Guide
        7. Marketing authorization for pharmaceutical
        8. Approval of follow-on biologics in Mexico
        9. Mexican Linkage Gazette April 2011
        10. Patent Prosecution Highway in Mexico
        11. 37 more items...
      3. Copyright Law Articles
        1. Advertising in social media networks
        2. Technology challenges digital rights
        3. Exceptions to copyright protection and the permitted uses of copyright works in the hi-tech and digital sectors
        4. Derechos sobre producción audiovisual
        5. How Latin America tackles cutting-edge IP issues
        6. Copyright Litigation 2010
        7. Legislation and enforcement - Copyrights 2010
        8. Valuing folklore
        9. Protecting novel ideas
        10. Mexico's fair use balancing act
        11. 100 more items...
      4. Corporate Law Articles
        1. Mexico issues Personal Data Protection Rules
        2. How data affects innovation
        3. A practical cross-border
        4. New registry for security interests
        5. The International Comparative Legal Guide to: Merger Control 2011
        6. The International Comparative Legal Guide to: Merger Control 2010
        7. Due diligence issues to consider in M&A
        8. Income expectations in licensing
        9. The reasons for valuation
        10. Amendments proposed to franchise regulation
      5. IP Litigation, ADR Articles
        1. Scope of new specialised courts widened
        2. Reform of preliminary injunctions
        3. Mexican Patent Office excludes Formulation Patents from Linkage Gazette
        4. Mexico gets ready to approve biocomparable drugs
        5. Mexico's hotel for the stars highlights power in the name
        6. Supreme Court upholds the worth of formulation patents
        7. Getting the Deal Through - Patents 2010
        8. Getting the Deal Through Trademarks 2010
        9. Trademark enforcement
        10. Venues for appealing IMPI decisions
        11. 15 more items...
      6. Regulatory Law Articles
        1. Recent amendment to the Federal Law for Consumer Protection
        2. Amendments to the Federal Law for Consumer Protection
        3. Mexico issues Personal Data Protection Rules
        4. New Regulations Pending
        5. Marketing authorization for pharmaceutical products to foreign applicants
        6. Data Package Exclusivity (DPE)
        7. Supreme Court upholds the worth of formulation patents
        8. Pharmaceutical trademarks
        9. Framework for biotherapeutic products established
        10. Pharmaceutical Advertising 2009
        11. 4 more items...
      7. Licensing, Tech Transfer Articles
        1. Creating a secure franchise system
      8. Anti-Piracy, Anti-Counterfeiting Articles
        1. New register against counterfeits
        2. Beat the counterfeiters in Mexico
        3. Battling counterfeits through Customs
        4. Getting the Deal Through Trademarks 2010
        5. Enforcing plant variety rights in Mexico
        6. Pharmaceutical Trademarks 2009
        7. Internet Issues
        8. Anti-counterfeiting 2009
        9. Vegetal variety rights enforced
        10. New Customs rules lead to seizures
        11. 3 more items...
      9. Media, Sports & Entertainment Focused Articles
        1. Advertising in social media networks
        2. Whither Rental Rights?
        3. Improved protection for personalities
      10. Life Sciences Focused Articles
        1. Latin America Roundtable
        2. New regulations pending
        3. The International Comparative
        4. Approval of follow-on biologics in Mexico
        5. Global Pharmaceutical Linkage Regulations:
        6. Life Sciences Handbook 2011 - Country Q&A
        7. Supreme Court upholds the worth of formulation patents
        8. Repercussions expected on medicine advertising campaign in Mexico
        9. Framework for biotherapeutic products established
        10. Pharmaceutical Trademarks 2009
        11. 1 more item...
    2. Webinar Archive
      1. Webinar - Changes to Mexican Patent and Healthcare Laws for Life Sciences
      2. Webinar - Digital Rights Issues in Copyright Law
      3. Webinar - Data Package Exclusivity Rights in Latin America
    3. Recognition
    4. News
      1. Mexico subscribes Madrid Protocol
      2. Presumed Guilty - How can a law firm help win an Emmy?
      3. New rules came in force to speed timeframes in administrative appeal proceedings
      4. Recent reforms to the Mexican Industrial Property Law dealing with trademark priority rights
      5. Olivares & Cia. ranking
      6. Data Package Exclusivity (DPE)
      7. Mr. Sergio Olivares Sr's Passing
      8. Pharma Linkage Regulations Supreme Court Decision
      9. Managing IP magazine has recognized Olivares & Cia. as the leading firm for patent work in Mexico
      10. Mexican Congress amends the Patent Law
      11. 1 more item...
  5. Events
  6. Offices
  7. Contact Us
  8. Quick guide to Mexico’s regulatory system
    1. Patent regulatory overview
    2. Trademark regulatory overview
    3. Copyright regulatory overview
    4. Corporate & Commercial Regulatory overview

Home » Knowledge & Resources » Articles » Patent Law Articles » Mexico to Issue Regulations for Approval of "Biocomparable" Drugs

Mexico to Issue Regulations for Approval of "Biocomparable" Drugs

By Juan Luis Serrano
Patents Doc, 2010
The Mexican General Health Law was reformed on June 11, 2009 to include an article 222 bis, which defined biotechnological drugs, and allowed for the approval of "biocomparables."  The decree came into force on September 8, 2009, and the Ministry of Health had a 180-day period to issue all specific regulations pertaining to the approval of these biocomparables.
Even though the 180-day period expired on March 8, 2010, work on the project of regulations has continued, with input being provided by both the Mexican Association of Pharmaceutical Research (AMIIF) and the National Association of Drug Manufacturers (ANAFAM).
This past week, COFEPRIS (the Mexican regulatory authority) made the project of regulations available to the public, through the official website of the Federal Commission for Regulatory Improvement (COFEMER).
At this point, a period of 30 working days has been given to any interested party that wishes to provide comments to this project through COFEMER's website, after which the project can be either published or further analyzed.
The main items in this project are:
  • A definition of comparability tests between an innovator and a biocomparable drug.
  • An indication that biocomparable drugs will use the same name for the active ingredient as the innovator.
  • The Health law regulations currently contain a 3-year period Roche-Bolar-like research exemption (related to the possibility of submitting an application for a marketing authorization before patent expiration, with intent to launch after the date of expiry).  This 3-year period is eliminated, and the submission can now be made at any time.  The modification in the corresponding article will also be applicable to chemical drugs.
  • The timelines that COFEPRIS will have for approval of both innovator and biocomparable drugs are established.
The first of these documents is an official communication from COFEMER to COFEPRIS (the authority which oversees approvals) referring to the regulatory impact that the provisions will have, which was made public on August 9, 2010.  COFEMER is requesting, amongst other things, the following:
- A justification for the elimination of the 3-year period in the Roche-Bolar-like research exemption in order to verify compliance of provisions in the Industrial Property Law.
- Justification for each requirement to approve biocomparable drugs.
- Additional information on cost impacts that the new regulations will have on industry participants.
- Additional information on reductions of public health expenditures derived from the regulations.
This communication has been delivered by COFEPRIS which will have to make the necessary justifications and adjustments to its proposal, before submitting anew to COFEMER.  There is no specific deadline contemplated for this purpose.  After the project is revised, if modifications are made, a new 30-day period will be granted to the general public to provide comments.
The second document contains a review by the Mexican Association of Pharmaceutical Laboratories (AMELAF) with a proposal for modifications to the project of regulations.  In this proposal, the main items are the following:
- Concerning the Roche-Bolar Mexican Supreme Court Decides on Broad Interpretation of Linkage Regulations").  This specific proposal is very likely to be contended by AMIIF, and/or individual patent holders.-like exemption, AMELAF is proposing to change the wording in order for linkage review by COFEPRIS to be made only in regards to the first "molecule" (active ingredient) patent, which would be applicable both to biotech and chemical drugs.  This goes directly against the decision by the Mexican Supreme Court, which interpreted linkage regulations to include patents covering pharmaceutical formulations as well (see "
- AMELAF is also proposing to make most regulatory requirements for the approval of a biocomparable drug subject to the discretion of the Ministry of Health on a case by case basis.  The current project contains mandatory pre-clinical and clinical trials, pharmacodinamics studies, immunity response studies in animals and in vivo studies.  The proposal by AMELAF is to make all of these requirements applicable "if necessary."
Whereas this proposal could have some merit in order to avoid studies that would prove to be unnecessary for specific drugs, it should be allowed only if a correlating provision providing for regulatory exclusivity is passed, in order to maintain a balance between the innovators making the initial studies and subsequent market entrants.  No such provision is contained in the project.
- Additionally, AMELAF is proposing that the term for COFEPRIS to approve a biotech drug be reduced from 235 to 180 working days, and that, if that term expires without a response, then the application is understood as granted.  This last item is not likely to be approved, as it could result in the authorization of drugs without full review of the applications by the corresponding authority, which might generate sanitary risks.